http://www.raredr.com/conferences/asco2017/verstovsek-phase-2-ruxolitinib-azacytidine
Serge Verstovsek, MD on the Phase 2 Study Involving Ruxolitinib with Azacytidine

Serge Verstovsek, MD



At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Rare Disease Report sat down with Serge Verstovsek, MD of the MD Anderson Cancer Center to discuss the study of the combination of therapies ruxolitinib and azacytidine in treating myelofibrosis patients.

The study, presented in an abstract, concluded that the combination showed an International Working Group (IWG)-response rate of 49% in pts with myelodysplastic/myleoproliferative neoplasms (MDS/MPNs), and was well-tolerated overall.

For the full interview, check out our article from Monday, 06/05.

For more from ASCO, check out our Conference Coverage page.
Printer Printing...
$content$